Isomorphic Labs nears $2 billion funding round for AI drug discovery
The AMW Read
A $2B round for AI drug-discovery platform meaningfully updates the segment's capital baseline; cross-§D trigger met by explicit billion-dollar figure.
Isomorphic Labs nears $2 billion funding round for AI drug discovery
Isomorphic Labs, the DeepMind spinout focused on AI-driven drug discovery, is nearing a $2 billion funding round, according to a report from Tech in Asia. The company, founded by Demis Hassabis and operating under Alphabet, applies AlphaFold-derived models to accelerate small-molecule drug design and target identification.
This round, if confirmed, would represent one of the largest capital raises in the AI-first biotech vertical, signaling that investors are willing to make billion-dollar bets on computational drug discovery platforms. The funding would place Isomorphic Labs alongside Recursion Pharmaceuticals and Insitro as the most capitalized players in the segment, reinforcing the thesis that AI-native biology platforms can command enterprise-scale valuations without a marketed drug.
The raise also exemplifies the 'capital-compression' pattern observed in segment 06 — large rounds concentrate into a small number of well-capitalized platforms while earlier-stage peers face a funding squeeze. For the broader AI ecosystem, it underscores that frontier-model labs like DeepMind can spin out domain-specific vertical applications that attract sovereign-wealth and crossover-investor interest, extending the 'hyperscaler distribution' moat into life sciences.